Tarceva first-line NSCLC Phase II data

Researchers from the Dana-Farber Cancer Institute presented data from a Phase II trial of Tarceva erlotinib as a first-line monotherapy to treat advanced non-small cell lung cancer (NSCLC) at the Cong...